Abstract
To clarify the way in which the clinical response to levodopa changes with the progression of Parkinson's disease, a longitudinal study was performed to quantify motor response characteristics to single doses of levodopa by mouth over three years in 23 patients with fluctuating motor function. A significant increase in motor disability in "on" (time of peak motor improvement) and "off" (before levodopa dose) phases occurred and "on" phase dyskinesia increased by 24%, though the amplitude of motor response was conserved. There was no evidence of progressive loss of response of certain motor deficits affecting axial muscles and gait. The mean duration of motor response decreased by 17%. Both shortening of response duration and increase in "off" phase disability contribute to the development of motor fluctuations. A short response time to the levodopa test dose was not an invariable finding in patients with severe fluctuations, whereas all had large response amplitudes and high "off" phase disability scores. Patients who have developed motor fluctuations may continue to respond to dopaminergic treatment until late in the disease course, despite the unstable nature of their responses.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blin J., Dubois B., Bonnet A. M., Vidailhet M., Brandabur M., Agid Y. Does ageing aggravate parkinsonian disability? J Neurol Neurosurg Psychiatry. 1991 Sep;54(9):780–782. doi: 10.1136/jnnp.54.9.780. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bonnet A. M., Loria Y., Saint-Hilaire M. H., Lhermitte F., Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology. 1987 Sep;37(9):1539–1542. doi: 10.1212/wnl.37.9.1539. [DOI] [PubMed] [Google Scholar]
- Fabbrini G., Juncos J., Mouradian M. M., Serrati C., Chase T. N. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol. 1987 Apr;21(4):370–376. doi: 10.1002/ana.410210409. [DOI] [PubMed] [Google Scholar]
- Hoehn M. M. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. Acta Neurol Scand. 1985 Feb;71(2):97–106. doi: 10.1111/j.1600-0404.1985.tb03173.x. [DOI] [PubMed] [Google Scholar]
- Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kempster P. A., Frankel J. P., Bovingdon M., Webster R., Lees A. J., Stern G. M. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):718–723. doi: 10.1136/jnnp.52.6.718. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Klawans H. L., Jr, Garvin J. S. Treatment of parkinsonism with L-dopa (study of 105 patients). Dis Nerv Syst. 1969 Nov;30(11):737–746. [PubMed] [Google Scholar]
- Rogers D., Lees A. J., Smith E., Trimble M., Stern G. M. Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study. Brain. 1987 Jun;110(Pt 3):761–776. doi: 10.1093/brain/110.3.761. [DOI] [PubMed] [Google Scholar]
- Shaw K. M., Lees A. J., Stern G. M. The impact of treatment with levodopa on Parkinson's disease. Q J Med. 1980;49(195):283–293. [PubMed] [Google Scholar]